Therapeutic targeting of the JAK/STAT pathway

Basic and Clinical Pharmacology and Toxicology

Volumn 114, Issue 1, 2014, Pages 18-23

  Aittomäki, Saara ^a,b   Pesu, Marko ^a,b,c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c PIRKANMAA HOSPITAL DISTRICT   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; ADELATINIB; BARICITINIB; FEDRATINIB; JANUS KINASE; JANUS KINASE INHIBITOR; LESTAURTINIB; MOMELOTINIB; PACRITINIB; PRALNACASAN; RUXOLITINIB; STAT PROTEIN; TOFACITINIB;

CANCER CELL; CANCER GROWTH; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; INTRACELLULAR SIGNALING; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS;

HARNESS;

ANIMALS; AUTOIMMUNE DISEASES; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; JANUS KINASES; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; PYRROLES; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84890806562     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12164     Document Type: Review

References (47)

1. O'Shea JJ, Gadina M, Kanno Y. Cytokine signaling: birth of a pathway. J Immunol 2011;187:5475-8.
2. Ihle JN. Cytokine receptor signalling. Nature 1995;377:591-4.
3. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012;36:503-14.
4. Laurence A, Pesu M, Silvennoinen O, O'Shea J. JAK kinases in health and disease: an update. Open Rheumatol J 2012;6:232-44.
5. Vahedi G, Takahashi H, Nakayamada S, Sun HW, Sartorelli V, Kanno Y, et al. STATs shape the active enhancer landscape of T cell populations. Cell 2012;151:981-93.
6. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013;368:161-70.
7. O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012;36:542-50.
8. Kaplan MH, Grusby MJ. Regulation of T helper cell differentiation by STAT molecules. J Leukoc Biol 1998;64:2-5.
9. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998;16:293-322.
10. Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O'Shea JJ. The janus kinases (jaks). Genome Biol 2004;5:253.
11. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Therapeutic targeting of janus kinases. Immunol Rev 2008;223:132-42.
12. Pesu M. Mutant JAK3 FERMents ATLL. Blood 2011;118:3759-60.
13. Ungureanu D, Wu J, Pekkala T, Niranjan Y, Young C, Jensen ON, et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 2011;18:971-6.
14. Bandaranayake RM, Ungureanu D, Shan Y, Shaw DE, Silvennoinen O, Hubbard SR. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat Struct Mol Biol 2012;19:754-9.
15. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995;270:797-800.
16. Yoshimura A, Misawa H. Physiology and function of the erythropoietin receptor. Curr Opin Hematol 1998;5:171-6.
17. Li Z, Gakovic M, Ragimbeau J, Eloranta ML, Ronnblom L, Michel F, et al. Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent. J Immunol 2013;190:2335-44.
18. Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the jaks in cytokine-induced biologic responses. Cell 1998;93:373-83.
19. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998;93:397-409.
20. Thomis DC, Gurniak CB, Tivol E, Sharpe AH, Berg LJ. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 1995;270:794-7.
21. Karaghiosoff M, Neubauer H, Lassnig C, Kovarik P, Schindler H, Pircher H, et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 2000;13:549-60.
22. Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, et al. Mutations of jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995;377:65-8.
23. Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O'Shea JJ. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 2005;203:127-42.
24. Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, Tsuchiya S, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006;25:745-55.
25. Kilic SS, Hacimustafaoglu M, Boisson-Dupuis S, Kreins AY, Grant AV, Abel L, et al. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J Pediatr 2012;160:1055-7.
26. Pesu M, O'Shea J, Hennighausen L, Silvennoinen O. Identification of an acquired mutation in Jak2 provides molecular insights into the pathogenesis of myeloproliferative disorders. Mol Interv 2005;5:211-5.
27. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
28. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
29. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
30. Kofoed EM, Hwa V, Little B, Woods KA, Buckway CK, Tsubaki J, et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med 2003;349:1139-47.
31. Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008;452:773-6.
32. Siegel AM, Heimall J, Freeman AF, Hsu AP, Brittain E, Brenchley JM, et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity 2011;35:806-18.
33. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012;366:1905-13.
34. Rajala HL, Eldfors S, Kuusanmaki H, van Adrichem AJ, Olson T, Lagstrom S, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 2013;121:4541-50.
35. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007;357:977-86.
36. Korman BD, Kastner DL, Gregersen PK, Remmers EF. STAT4: genetics, mechanisms, and implications for autoimmunity. Curr Allergy Asthma Rep 2008;8:398-403.
37. Wang BX, Platanias LC, Fish EN. STAT activation in malignancies: roles in tumor progression and in the generation of antineoplastic effects of IFNs. J Interferon Cytokine Res 2013;33:181-8.
38. O'Shea JJ, Pesu M, Borie DC, Changelian PS. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004;3:555-64.
39. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27.
40. Internet. http://www.jakafi.com (last accessed on October 2013).
41. Sonbol MB, Firwana B, Zarzour A, Morad M, Rana V, Tiu RV. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther Adv Hematol 2013;4:15-35.
42. O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013;72(Suppl 2):ii111-5.
43. Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 2011;10:127-40.
44. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, et al. Prevention of organ allograft rejection by a specific janus kinase 3 inhibitor. Science 2003;302:875-8.
45. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32.
46. Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690, 550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010;7:41.
47. Internet. http://www.xeljanz.com (last accessed on October 2013).